Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms

2026-02-24 - 12:13

Investors: Ashley Dong Director, Investor Relations (929) 687-1614 adong@axsome.com Read More